<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">20346635</PMID>
        <DateCompleted>
            <Year>2010</Year>
            <Month>07</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-7862</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title>
                <ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>421-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euroneuro.2010.02.011</ELocationID>
            <Abstract>
                <AbstractText>Dopamine agonists reduce prepulse inhibition (PPI) of startle in rats. While it is used to predict antipsychotic efficacy, the specific receptor subtypes mediating this effect of dopamine agonists remain unclear. We characterized the effects of sumanirole, a highly selective D2 agonist, on PPI in rats. Sumanirole decreased PPI at 60-120 ms prepulse intervals, and increased PPI at 10-20 ms intervals. PPI deficits were antagonized by low doses of the preferential D2 antagonist L741626, supporting a D2 mechanism of action. Sumanirole is a valuable tool for parsing the role of dopamine receptor subtypes in the regulation of PPI.</AbstractText>
                <CopyrightInformation>2010 Elsevier B.V. and ECNP. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Weber</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, UCSD School of Medicine, 9500 Gilman Dr., La Jolla, CA 92093-0804, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Wei-Li</ForeName>
                    <Initials>WL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Breier</LastName>
                    <ForeName>Michelle R</ForeName>
                    <Initials>MR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Alex</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Millan</LastName>
                    <ForeName>Mark J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swerdlow</LastName>
                    <ForeName>Neal R</ForeName>
                    <Initials>NR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>MH01436</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 MH068366</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K02 MH001436-10</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MH68366</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 MH068366-06</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K02 MH001436</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>03</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Eur Neuropsychopharmacol</MedlineTA>
            <NlmUniqueID>9111390</NlmUniqueID>
            <ISSNLinking>0924-977X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2OI87T3R1B</RegistryNumber>
                <NameOfSubstance UI="C108539">U 95666E</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000161" MajorTopicYN="N">Acoustic Stimulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004192" MajorTopicYN="N">Discrimination, Psychological</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007035" MajorTopicYN="N">Hypothermia</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName>
                <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050637" MajorTopicYN="N">Receptors, Dopamine D3</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013216" MajorTopicYN="N">Reflex, Startle</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>02</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>7</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20346635</ArticleId>
            <ArticleId IdType="pii">S0924-977X(10)00044-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.euroneuro.2010.02.011</ArticleId>
            <ArticleId IdType="pmc">PMC2864324</ArticleId>
            <ArticleId IdType="mid">NIHMS185985</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Biol Psychiatry. 2000 Apr 1;47(7):670-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10745061</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2009 Sep;206(1):73-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19513698</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2000 Jun;293(3):1048-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10869410</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2002 Nov;303(2):791-804</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12388666</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Investig Drugs. 2003 Jan;4(1):77-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12625034</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2004 Jul;174(3):341-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14985929</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2004 Aug;174(4):452-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15300359</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 1997 Feb 28;40(5):639-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9057850</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2005 Sep;314(3):1248-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15980060</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2007 Aug;193(2):159-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17393143</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Behav Brain Res. 2007 Aug 22;182(1):1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17570538</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2008 Aug;199(3):331-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18568339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Behav Pharmacol. 2008 Dec;19(8):786-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19020413</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2009 Apr;203(2):317-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18807248</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacol Biochem Behav. 2009 Aug;93(2):141-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19426754</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2009 Sep;205(4):689-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19506839</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Pharmacol. 2000 Apr 7;394(1):47-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10771033</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
